Low Annexin A1 level in HTLV-1 infected patients is a potential biomarker for the clinical progression and diagnosis of HAM/TSP

Abstract Background Human T-lymphotropic virus 1 (HTLV-1) is etiologically associated with the chronic inflammatory neurodegenerative disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) Annexin A1 (AnxA1) an anti-inflammatory protein proposed neuroprotective and anti-neuroinflammatory functions. We hypothesized that ANXA1 gene expression may be dysregulated in HTLV-1-infected HAM/TSP patients. Methods This study involved 37 individuals infected HTLV-1, including 21 asymptomatic (AS) carriers 16 HAM/TSP, a control group of 30 negative for HTLV-1 HTLV-2. For AS HTLV-1-positive patients, formyl peptide receptor ( FPR1 , FPR2 FPR3 ) proviral load (PVL) peripheral blood cells were evaluated by real-time quantitative PCR (qPCR), plasma AnxA1 levels determined enzyme-linked immunosorbent assay (ELISA). Results was increased compared groups, but differences not statistically significant. higher patients than controls (AS, p = 0.0032; < 0.0001). Plasma 0.0045), PVL 0.0162). The use combined ROC curve using significantly sensitivity specificity to predict progression (AUC 0.851 AUC 0.937, respectively, 1000). Conclusions Our results suggest Serological detection association provide prognostic biomarker disease.